poisar

Stock

Protagonist Therapeutics, Inc. PTGX

$155.10+2.43%

Overview

PTGX market data

Price History

PTGX price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
115.35
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.05
Diluted earnings per share over the trailing twelve months.
Beta
1.49
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
29.4%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$50.58 – $151.88
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $9.6B · P/B 8.88 · P/S 33.92.

Company News

10 captured
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder DrugBenzinga · Aug 13, 2026, 5:07 PM
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170Benzinga · Aug 10, 2026, 6:18 PM
Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $173Benzinga · Aug 10, 2026, 2:50 PM
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For MondayBenzinga · Aug 10, 2026, 12:07 PM
Goldman Sachs Upgrades Protagonist Therapeutics to Buy, Raises Price Target to $186Benzinga · Aug 10, 2026, 9:53 AM
Protagonist Therapeutics shares are trading higher after Barclays raised its price target on the stock from $151 to $153.Benzinga · Aug 6, 2026, 5:41 PM
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $153Benzinga · Aug 6, 2026, 2:49 PM
Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M EstimateBenzinga · Aug 5, 2026, 10:07 PM
8-K filing — Protagonist Therapeutics, Inc (PTGX)SEC EDGAR · Aug 5, 2026, 8:11 PM
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151Benzinga · Jul 14, 2026, 11:39 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock